A detailed history of Driehaus Capital Management LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Driehaus Capital Management LLC holds 696,607 shares of NUVL stock, worth $71.8 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares
696,607
Previous 696,607 -0.0%
Holding current value
$71.8 Million
Previous $52.8 Million -0.0%
% of portfolio
0.57%
Previous 0.57%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$62.76 - $81.61 $1.49 Million - $1.94 Million
23,730 Added 3.53%
696,607 $52.8 Million
Q1 2024

May 15, 2024

SELL
$72.35 - $88.99 $19.2 Million - $23.6 Million
-264,851 Reduced 28.24%
672,877 $50.5 Million
Q4 2023

Feb 14, 2024

SELL
$42.42 - $80.28 $12.8 Million - $24.2 Million
-301,675 Reduced 24.34%
937,728 $69 Million
Q3 2023

Nov 14, 2023

SELL
$39.12 - $49.85 $7.88 Million - $10 Million
-201,327 Reduced 13.97%
1,239,403 $57 Million
Q2 2023

Aug 14, 2023

BUY
$23.58 - $44.68 $900,873 - $1.71 Million
38,205 Added 2.72%
1,440,730 $60.8 Million
Q1 2023

May 15, 2023

SELL
$25.42 - $33.52 $6.88 Million - $9.07 Million
-270,689 Reduced 16.18%
1,402,525 $36.6 Million
Q4 2022

Feb 14, 2023

BUY
$18.46 - $36.37 $1.79 Million - $3.52 Million
96,888 Added 6.15%
1,673,214 $49.8 Million
Q3 2022

Nov 14, 2022

BUY
$13.55 - $19.92 $2.36 Million - $3.46 Million
173,875 Added 12.4%
1,576,326 $30.6 Million
Q2 2022

Aug 15, 2022

BUY
$7.4 - $15.07 $1.79 Million - $3.65 Million
242,383 Added 20.89%
1,402,451 $19 Million
Q1 2022

May 16, 2022

SELL
$11.65 - $19.57 $240,316 - $403,689
-20,628 Reduced 1.75%
1,160,068 $16.1 Million
Q4 2021

Feb 14, 2022

BUY
$18.01 - $30.1 $2.31 Million - $3.86 Million
128,302 Added 12.19%
1,180,696 $22.5 Million
Q3 2021

Nov 15, 2021

BUY
$18.25 - $38.35 $19.2 Million - $40.4 Million
1,052,394 New
1,052,394 $23.7 Million

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $4.43B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Driehaus Capital Management LLC Portfolio

Follow Driehaus Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.